$INSP
Inspire Medical Systems, Inc. Stock $insp

$insp Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000160955022000023 Filed on May 03, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$69.38M	$40.35M
YoY Change	71.94%	89.03%
Cost Of Revenue	$10.00M	$5.981M
YoY Change	67.26%	81.41%
Gross Profit	$59.38M	$34.37M
YoY Change	72.76%	90.42%
Gross Profit Margin	85.58%	85.18%
Selling, General & Admin	$63.56M	$41.91M
YoY Change	51.67%	44.27%
% of Gross Profit	107.05%	121.93%
Research & Development	$11.87M	$8.154M
YoY Change	45.57%	49.94%
% of Gross Profit	19.99%	23.72%
Depreciation & Amortization	$359.0K	$234.0K
YoY Change	53.42%	25.13%
% of Gross Profit	0.6%	0.68%
Operating Expenses	$75.43M	$50.06M
YoY Change	50.69%	45.14%
Operating Profit	-$16.06M	-$15.69M
YoY Change	2.34%	-4.57%
Interest Expense	$527.0K	$523.0K
YoY Change	0.76%	-0.38%
% of Operating Profit
Other Income/Expense, Net	-$538.0K	-$504.0K
YoY Change	6.75%	-358.46%
Pretax Income	-$16.59M	-$16.19M
YoY Change	2.48%	-0.32%
Income Tax	$100.0K	$0.00
% Of Pretax Income
Net Earnings	-$16.69M	-$16.22M
YoY Change	2.95%	-0.18%
Net Earnings / Revenue	-24.06%	-40.19%
Basic Earnings Per Share	-$0.61	-$0.60
Diluted Earnings Per Share	-$0.61	-$0.60
COMMON SHARES
Basic Shares Outstanding	27.52M shares	27.14M shares
Diluted Shares Outstanding	27.52M shares	27.14M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$203.3M	$226.1M
YoY Change	-10.09%	66.62%
Cash & Equivalents	$203.3M	$182.3M
Short-Term Investments		$43.80M
Other Short-Term Assets	$2.444M	$1.600M
YoY Change	52.75%	14.29%
Inventory	$22.20M	$11.39M
Prepaid Expenses	$2.444M	$1.609M
Receivables	$34.54M	$21.65M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$262.5M	$260.8M
YoY Change	0.65%	67.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.334M	$6.791M
YoY Change	37.45%	118.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$9.796M
YoY Change
Other Assets	$454.0K	$200.0K
YoY Change	127.0%	-50.0%
Total Long-Term Assets	$27.24M	$12.63M
YoY Change	115.72%	22.55%
TOTAL ASSETS
Total Short-Term Assets	$262.5M	$260.8M
Total Long-Term Assets	$27.24M	$12.63M
Total Assets	$289.7M	$273.4M
YoY Change	5.96%	64.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.02M	$9.100M
YoY Change	87.05%	56.9%
Accrued Expenses	$13.90M	$10.37M
YoY Change	34.07%	31.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.25M
YoY Change
Total Short-Term Liabilities	$43.17M	$19.42M
YoY Change	122.26%	41.59%
LONG-TERM LIABILITIES
Long-Term Debt	$12.80M	$24.80M
YoY Change	-48.4%	0.81%
Other Long-Term Liabilities	$146.0K	$97.00K
YoY Change	50.52%	142.5%
Total Long-Term Liabilities	$146.0K	$97.00K
YoY Change	50.52%	142.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.17M	$19.42M
Total Long-Term Liabilities	$146.0K	$97.00K
Total Liabilities	$64.67M	$50.28M
YoY Change	28.6%	31.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$296.1M	-$253.6M
YoY Change	16.77%	29.11%
Common Stock	$28.00K	$27.00K
YoY Change	3.7%	12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$225.1M	$223.1M
YoY Change
Total Liabilities & Shareholders Equity	$289.7M	$273.4M
YoY Change	5.96%	64.97%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$16.69M	-$16.22M
YoY Change	2.95%	-0.18%
Depreciation, Depletion And Amortization	$359.0K	$234.0K
YoY Change	53.42%	25.13%
Cash From Operating Activities	-$12.75M	-$10.40M
YoY Change	22.57%	-29.6%
INVESTING ACTIVITIES
Capital Expenditures	$1.215M	$1.321M
YoY Change	-8.02%	418.04%
Acquisitions
YoY Change
Other Investing Activities	-$250.0K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$1.465M	-$1.321M
YoY Change	10.9%	-101.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.044M	$3.550M
YoY Change	-14.25%	351.08%
NET CHANGE
Cash From Operating Activities	-$12.75M	-$10.40M
Cash From Investing Activities	-$1.465M	-$1.321M
Cash From Financing Activities	$3.044M	$3.550M
Net Change In Cash	-$11.18M	-$8.170M
YoY Change	36.79%	-115.34%
FREE CASH FLOW
Cash From Operating Activities	-$12.75M	-$10.40M
Capital Expenditures	$1.215M	$1.321M
Free Cash Flow	-$13.96M	-$11.72M
YoY Change	19.12%	-22.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001609550
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1377674
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38468
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5500 Wayzata Blvd.
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Inspire Medical Systems, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Golden Valley
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55416
CY2022Q1	dei	City Area Code CityAreaCode	844
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	672-4357
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	INSP
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27591115	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	203291000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	214467000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	99000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	99000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34544000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34179000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	22198000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	17231000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2444000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2660000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	262477000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	268537000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	9796000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	9938000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9334000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8486000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7659000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7919000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	454000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	204000	USD
CY2022Q1	us-gaap	Assets Assets	289720000	USD
CY2021Q4	us-gaap	Assets Assets	295084000	USD
CY2022Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	17022000	USD
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	11665000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13896000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20454000	USD
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	12250000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9188000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	43168000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41307000	USD
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	12798000	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	15799000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8553000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8796000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	146000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	134000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	64665000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	66036000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-504000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16594000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27568004	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27568004	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27416106	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27416106	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	521308000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	508465000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-198000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-55000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-296083000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-279389000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	225055000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	229048000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	289720000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	295084000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69382000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40352000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10004000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5981000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	59378000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8154000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	63564000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	34371000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11870000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41906000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	75434000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	50060000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16056000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15689000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	34000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	57000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	527000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	523000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-45000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-538000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16193000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-16694000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-16216000	USD
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-143000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-20000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16837000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16236000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27517268	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27517268	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27144361	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27144361	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229048000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3087000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	569	shares
CY2022Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	205	shares
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	43000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	79000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9721000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-143000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16694000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	225055000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229747000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3550000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	73000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5997000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-20000	USD
CY2022Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16216000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	223131000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-16694000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-16216000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	359000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	234000	USD
CY2021Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-30000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	62000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	58000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	260000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	171000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9721000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5997000	USD
CY2022Q1	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	79000	USD
CY2021Q1	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	73000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	8000	USD
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	382000	USD
CY2021Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-3381000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4967000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2905000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-216000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-356000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5520000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1477000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6921000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3049000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12748000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10401000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1215000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1321000	USD
CY2022Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	250000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182348000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	466000	USD
CY2021Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1465000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1321000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3087000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3550000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	43000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3044000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3550000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11176000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8170000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	214467000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190518000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	203291000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	466000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	284000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1209000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-200000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-100000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of March 31, 2022 and December 31, 2021, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically not been significant.</span></div>
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5342000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3119000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16856000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14112000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	22198000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	17231000	USD
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	400000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12745000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11538000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3411000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3052000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9334000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8486000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	USD
CY2022Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10565000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	17655000	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	160000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	160000	USD
CY2022Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	438000	USD
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	468000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	673000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	312000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2060000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1859000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13896000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20454000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	468000	USD
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	159000	USD
CY2022Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	11000	USD
CY2021Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	178000	USD
CY2022Q1	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	41000	USD
CY2021Q1	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	71000	USD
CY2022Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	438000	USD
CY2021Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	266000	USD
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	15500000	USD
CY2021Q1	us-gaap	Advertising Expense AdvertisingExpense	9000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2022Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	70000	sqft
CY2022Q1	insp	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9108000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q1	insp	Incentive From Lessor Rent Abatement IncentiveFromLessorRentAbatement	2300000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7659000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7919000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	673000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	312000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8553000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8796000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9226000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y2M12D
CY2022Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.053
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	24500000	USD
CY2022Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2022Q1	insp	Defined Contribution Plan Annual Contribution Per Employee Maximum Eligible For Employer Match Percent DefinedContributionPlanAnnualContributionPerEmployeeMaximumEligibleForEmployerMatchPercent	0.06
CY2022Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2022Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9721000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5997000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9721000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5997000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2646235	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	80.41
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	397015000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	281554	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	228.40
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	151186	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	20.74
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	29820000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	13388	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	160.44
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2763215	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	98.37
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	437730000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1510689	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	49.56
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2022Q1	insp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable	312906000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	94200000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2022Q1	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69382000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40352000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2907786	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2758435	shares

Files In Submission

Name	View Source	Status
0001609550-22-000023-index-headers.html	Edgar Link	pending
0001609550-22-000023-index.html	Edgar Link	pending
0001609550-22-000023.txt	Edgar Link	pending
0001609550-22-000023-xbrl.zip	Edgar Link	pending
a2022-q1ex31x1.htm	Edgar Link	pending
a2022-q1ex31x2.htm	Edgar Link	pending
a2022-q1ex32x1.htm	Edgar Link	pending
a2022-q1ex32x2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
insp-20220331.htm	Edgar Link	pending
insp-20220331.xsd	Edgar Link	pending
insp-20220331_cal.xml	Edgar Link	unprocessable
insp-20220331_def.xml	Edgar Link	unprocessable
insp-20220331_g1.jpg	Edgar Link	pending
insp-20220331_htm.xml	Edgar Link	completed
insp-20220331_lab.xml	Edgar Link	unprocessable
insp-20220331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSP
Inspire Medical Systems, Inc. Stock $insp

2022 Q1 Form 10-Q Financial Statement

#000160955022000023 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP Inspire Medical Systems, Inc. Stock $insp

2022 Q1 Form 10-Q Financial Statement

#000160955022000023 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP
Inspire Medical Systems, Inc. Stock $insp